Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CASPIAN: Durvalumab +/- Tremelimumab + Chemotherapy in First-Line Extensive-Stage SCLC
NCT03043872Phase 3Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Mar 2017
- Primary completion
- Jan 2020
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 23
01
Overview
A Phase 3 trial of durvalumab, tremelimumab in small cell lung cancer (SCLC), sponsored by AstraZeneca. Started Mar 2017; status: active, not recruiting.
02
Drugs
durvalumabtremelimumab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT03043872.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03043872.